Chronic allograft injury: Mechanisms and potential treatment targets

Transplantation Reviews

Volumn 31, Issue 1, 2017, Pages 1-9

  Riella, Leonardo V ^a   Djamali, Arjang ^b   Pascual, Julio ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY MEDIATED REJECTION; BACTERIAL INFECTION; BIOPSY; BK VIRUS INFECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; DIAGNOSTIC TEST; GLOMERULONEPHRITIS; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOPATHOGENESIS; KIDNEY GRAFT REJECTION; LONG TERM SURVIVAL; NEPHROTOXICITY; PATIENT CARE; PREVENTIVE MEDICINE; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT REFUSAL; ALLOGRAFT; ALLOTRANSPLANTATION; CHRONIC DISEASE; DONOR; DRUG EFFECTS; FEMALE; FOLLOW UP; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MALE; NEEDLE BIOPSY; PROCEDURES; RISK ASSESSMENT; TIME FACTOR;

ALLOGRAFTS; BIOPSY, NEEDLE; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RISK ASSESSMENT; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 85008219759     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2016.10.005     Document Type: Review

References (100)

1. [1] Matas, A.J., Smith, J.M., Skeans, M.A., et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant 15 (2015), 1–34 [PubMed PMID: 25626344].
2. [2] Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) OPTN/SRTR 2010 Annual Data Report. 2010.
3. [3] Lamb, K.E., Lodhi, S., Meier-Kriesche, H.U., Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11 (2011), 450–462 [PubMed PMID: 20973913].
4. [4] El-Zoghby, Z., Stegall, M., Lager, D., et al. Identifying specific causes of kidney allograft loss. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 9 (2009), 527–535.
5. [5] Solez, K., Colvin, R.B., Racusen, L.C., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 7 (2007), 518–526 [PubMed PMID: 17352710].
6. [6] Cosio, F.G., Grande, J.P., Wadei, H., Larson, T.S., Griffin, M.D., Stegall, M.D., Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5 (2005), 2464–2472 [PubMed PMID: 16162196].
7. [7] Naesens, M., Kuypers, D.R., De Vusser, K., et al. Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 13 (2013), 86–99 [PubMed PMID: 23136888].
8. [8] Shishido, S., Asanuma, H., Nakai, H., et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14 (2003), 1046–1052 [PubMed PMID: 12660340].
9. [9] Sellares, J., de Freitas, D.G., Mengel, M., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12 (2012), 388–399 [PubMed PMID: 22081892].
10. [10] Butler, J.A., Roderick, P., Mullee, M., Mason, J.C., Peveler, R.C., Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 77 (2004), 769–776 [PubMed PMID: 15021846].
11. [11] Gaston, R.S., Cecka, J.M., Kasiske, B.L., et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90 (2010), 68–74 [PubMed PMID: 20463643].
12. [12] Cohen, D., Colvin, R.B., Daha, M.R., et al. Pros and cons for C4d as a biomarker. Kidney Int 81 (2012), 628–639 [PubMed PMID: 22297669, Pubmed Central PMCID: 3771104].
13. [13] Einecke, G., Sis, B., Reeve, J., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 9 (2009), 2520–2531 [PubMed PMID: 19843030].
14. [14] Haas, M., Mirocha, J., Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 11 (2011), 2123–2131 [PubMed PMID: 21827618].
15. [15] Sellares, J., Reeve, J., Loupy, A., et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 13 (2013), 971–983 [PubMed PMID: 23414212].
16. [16] Gloor, J., Stegall, M.D., Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 6 (2010), 297–306 [PubMed PMID: 20234355, Epub 2010/03/18. eng].
17. [17] Riella, L.V., Safa, K., Yagan, J., et al. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation 97 (2014), 1247–1252 [PubMed PMID: 24854670].
18. [18] Wiebe, C., Gibson, I.W., Blydt-Hansen, T.D., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12 (2012), 1157–1167 [PubMed PMID: 22429309].
19. [19] Everly, M.J., Rebellato, L.M., Haisch, C.E., et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95 (2013), 410–417 [PubMed PMID: 23380861].
20. [20] Djamali, A., Kaufman, D.B., Ellis, T.M., Zhong, W., Matas, A., Samaniego, M., Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 14 (2014), 255–271 [PubMed PMID: 24401076, Pubmed Central PMCID: 4285166].
21. [21] Briganti, E.M., Russ, G.R., McNeil, J.J., Atkins, R.C., Chadban, S.J., Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347 (2002), 103–109 [PubMed PMID: 12110738].
22. [22] Mulay, A.V., van Walraven, C., Knoll, G.A., Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 9 (2009), 804–811 [PubMed PMID: 19353768].
23. [23] Hickson, L.J., Gera, M., Amer, H., et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87 (2009), 1232–1239 [PubMed PMID: 19384172].
24. [24] Gallon, L., Leventhal, J., Skaro, A., Kanwar, Y., Alvarado, A., Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 366 (2012), 1648–1649 [PubMed PMID: 22533598].
25. [25] Le Quintrec, M., Lionet, A., Kamar, N., et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8 (2008), 1694–1701 [PubMed PMID: 18557729].
26. [26] Moroni, G., Longhi, S., Quaglini, S., et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant 28 (2013), 1305–1314 [PubMed PMID: 23229925].
27. [27] Odum, J., Peh, C.A., Clarkson, A.R., et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 9 (1994), 309–312 [PubMed PMID: 8052439].
28. [28] Wiseman, A.C., Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 54 (2009), 131–142 [PubMed PMID: 19394729].
29. [29] Randhawa, P., Brennan, D.C., BK virus infection in transplant recipients: an overview and update. Am J Transplant 6 (2006), 2000–2005 [PubMed PMID: 16771813].
30. [30] Sagedal, S., Hartmann, A., Nordal, K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66 (2004), 329–337 [PubMed PMID: 15200441].
31. [31] Detwiler, R.K., Singh, H.K., Bolin, P. Jr., Jennette, J.C., Cytomegalovirus-induced necrotizing and crescentic glomerulonephritis in a renal transplant patient. Am J Kidney Dis 32 (1998), 820–824 [PubMed PMID: 9820453].
32. [32] Nankivell, B.J., Borrows, R.J., Fung, C.L., O'Connell, P.J., Chapman, J.R., Allen, R.D., Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004), 557–565 [PubMed PMID: 15446315].
33. [33] Ekberg, H., Tedesco-Silva, H., Demirbas, A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007), 2562–2575 [PubMed PMID: 18094377].
34. [34] Ekberg, H., Bernasconi, C., Tedesco-Silva, H., et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 9 (2009), 1876–1885 [PubMed PMID: 19563339].
35. [35] Hricik, D.E., Formica, R.N., Nickerson, P., et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol 26 (2015), 3114–3122 [PubMed PMID: 25925687, Pubmed Central PMCID: 4657844].
36. [36] Snanoudj, R., Royal, V., Elie, C., et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 11 (2011), 2635–2646 [PubMed PMID: 21883915].
37. [37] Lamattina, J.C., Foley, D.P., Mezrich, J.D., et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol 6 (2011), 1851–1857 [PubMed PMID: 21784823, Pubmed Central PMCID: 3359532].
38. [38] Maggiore, U., Oberbauer, R., Pascual, J., et al. Strategies to increase the donor pool and access to kidney transplantation: an international perspective. Nephrol Dial Transplant 30 (2015), 217–222 [PubMed PMID: 24907023, Pubmed Central PMCID: 4309190].
39. [39] Rose, C., Schaeffner, E., Frei, U., Gill, J., Gill, J.S., A lifetime of allograft function with kidneys from older donors. J Am Soc Nephrol 26 (2015), 2483–2493 [PubMed PMID: 25814474, Pubmed Central PMCID: 4587698].
40. [40] Freedman, B.I., Pastan, S.O., Israni, A.K., et al. APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 100 (2016), 194–202 [PubMed PMID: 26566060, Pubmed Central PMCID: 4684443].
41. [41] Riella, L.V., Sheridan, A.M., Testing for high-risk APOL1 alleles in potential living kidney donors. Am J Kidney Dis 66 (2015), 396–401 [PubMed PMID: 26049628].
42. [42] Giral, M., Foucher, Y., Karam, G., et al. Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol 21 (2010), 1022–1029 [PubMed PMID: 20488949, Pubmed Central PMCID: 2900958].
43. [43] Brenner, B.M., Cohen, R.A., Milford, E.L., In renal transplantation, one size may not fit all. J Am Soc Nephrol 3 (1992), 162–169 [PubMed PMID: 1391717].
44. [44] Pascual, J., Perez-Saez, M.J., Mir, M., Crespo, M., Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplant Rev 26 (2012), 280–290 [PubMed PMID: 22902496].
45. [45] Hricik, D.E., Nickerson, P., Formica, R.N., et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 13 (2013), 2634–2644 [PubMed PMID: 23968332, Pubmed Central PMCID: 3959786].
46. [46] Suthanthiran, M., Muthukumar, T., Urinary-cell mRNA and acute kidney-transplant rejection. N Engl J Med 369 (2013), 1860–1861 [PubMed PMID: 24195554].
47. [47] Crespo, M., Yelamos, J., Redondo, D., et al. Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. Am J Transplant 15 (2015), 806–814 [PubMed PMID: 25656947].
48. [48] Konvalinka, A., Tinckam, K., Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol 26 (2015), 1489–1502 [PubMed PMID: 25804279, Pubmed Central PMCID: 4483594].
49. [49] Crespo, M., Torio, A., Mas, V., et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?. Transpl Immunol 29 (2013), 28–33 [PubMed PMID: 23907088].
50. [50] Lefaucheur, C., Nochy, D., Andrade, J., et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9 (2009), 1099–1107 [PubMed PMID: 19422335, Epub 2009/05/09. eng].
51. [51] Lefaucheur, C., Viglietti, D., Bentlejewski, C., et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 27 (2016), 293–304 [PubMed PMID: 26293822, Pubmed Central PMCID: 4696574].
52. [52] Henderson, L.K., Nankivell, B.J., Chapman, J.R., Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice. Am J Transplant 11 (2011), 1570–1575 [PubMed PMID: 21797971].
53. [53] Moreso, F., Carrera, M., Goma, M., et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 93 (2012), 41–46 [PubMed PMID: 22094957].
54. [54] Loupy, A., Vernerey, D., Tinel, C., et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 26 (2015), 1721–1731 [PubMed PMID: 25556173, Pubmed Central PMCID: 4483584].
55. [55] Gallagher, M., Jardine, M., Perkovic, V., et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 87 (2009), 1877–1883 [PubMed PMID: 19543068].
56. [56] Gallagher, M.P., Hall, B., Craig, J., et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 78 (2004), 1653–1660 [PubMed PMID: 15591955].
57. [57] Sharif, A., Shabir, S., Chand, S., Cockwell, P., Ball, S., Borrows, R., Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 22 (2011), 2107–2118 [PubMed PMID: 21949096, Pubmed Central PMCID: 3280000].
58. [58] Riella, L.V., Sayegh, M.H., T-cell co-stimulatory blockade in transplantation: two steps forward one step back!. Expert Opin Biol Ther 13 (2013), 1557–1568 [PubMed PMID: 24083381].
59. [59] Safa, K., Riella, L.V., Chandraker, A., Beyond calcineurin inhibitors: emerging agents in kidney transplantation. Curr Opin Nephrol Hypertens 22 (2013), 689–697 [PubMed PMID: 24100221].
60. [60] Vincenti, F., Rostaing, L., Grinyo, J., et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374 (2016), 333–343 [PubMed PMID: 26816011].
61. [61] Murakami, N., Riella, L.V., Funakoshi, T., Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 14 (2014), 2317–2327 [PubMed PMID: 25146383].
62. [62] Cibrik, D., Silva, H.T. Jr., Vathsala, A., et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 95 (2013), 933–942 [PubMed PMID: 23422495].
63. [63] Tedesco Silva, H. Jr., Cibrik, D., Johnston, T., et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 10 (2010), 1401–1413 [PubMed PMID: 20455882].
64. [64] Pascual, J.S.T., Chadban, S., Citterio, F., et al. Open Access J Clin Trials 6 (2014), 45–54.
65. [65] Opelz, G., Dohler, B., Collaborative, T.S., Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 5 (2005), 2725–2731 [PubMed PMID: 16212633].
66. [66] Carpenter, M.A., John, A., Weir, M.R., et al. BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. J Am Soc Nephrol 25 (2014), 1554–1562 [PubMed PMID: 24627349, Pubmed Central PMCID: 4073424].
67. [67] Knoll, G.A., Fergusson, D., Chasse, M., et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diab Endocrinol 4 (2016), 318–326 [PubMed PMID: 26608067].
68. [68] Weir, M.R., Burgess, E.D., Cooper, J.E., et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol 26 (2015), 1248–1260 [PubMed PMID: 25653099. Pubmed Central PMCID: 4446882].
69. [69] Moers, C., Smits, J.M., Maathuis, M.H., et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 360 (2009), 7–19 [PubMed PMID: 19118301].
70. [70] El-Zoghby, Z.M., Stegall, M.D., Lager, D.J., et al. Identifying specific causes of kidney allograft loss. Am J Transplant 9 (2009), 527–535 [PubMed PMID: 19191769].
71. [71] Gloor, J.M., Cosio, F.G., Rea, D.J., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6 (2006), 1841–1847 [PubMed PMID: 16780546].
72. [72] Loupy, A., Suberbielle-Boissel, C., Zuber, J., et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 89 (2010), 1403–1410 [PubMed PMID: 20386362].
73. [73] Vo, A.A., Choi, J., Cisneros, K., et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 98 (2014), 312–319 [PubMed PMID: 24770617].
74. [74] Aubert, O., Suberbielle, C., Gauthe, R., Francois, H., Obada, E.N., Durrbach, A., Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant. Transplantation 97 (2014), 946–952 [PubMed PMID: 24759674].
75. [75] Stegall, M.D., Diwan, T., Raghavaiah, S., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11 (2011), 2405–2413 [PubMed PMID: 21942930, Epub 2011/09/29. eng].
76. [76] Vo, A.A., Choi, J., Kim, I., et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + Intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99 (2015 Nov), 2356–2363 [PubMed PMID: 26018350].
77. [77] Vo, A.A., Zeevi, A., Choi, J., et al. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99 (2015), 299–308 [PubMed PMID: 25606785].
78. [78] Sautenet, B., Blancho, G., Buchler, M., et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100 (2016), 391–399 [PubMed PMID: 26555944].
79. [79] Fehr, T., Rusi, B., Fischer, A., Hopfer, H., Wuthrich, R.P., Gaspert, A., Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 87 (2009), 1837–1841 [PubMed PMID: 19543061].
80. [80] Redfield, R.R., Ellis, T.M., Zhong, W., et al. Current outcomes of chronic active antibody mediated rejection – a large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol 77 (2016), 346–352 [PubMed PMID: 26867813].
81. [81] Smith, R.N., Malik, F., Goes, N., et al. Partial therapeutic response to rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 27 (2012), 107–113 [PubMed PMID: 22960786, Pubmed Central PMCID: 3728650].
82. [82] Waiser, J., Budde, K., Schutz, M., et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 27 (2012), 1246–1251 [PubMed PMID: 21852274].
83. [83] Cooper, J.E., Gralla, J., Klem, P., Chan, L., Wiseman, A.C., High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation 97 (2014), 1253–1259 [PubMed PMID: 24937199].
84. [84] Archdeacon, P., Chan, M., Neuland, C., et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 11 (2011), 896–906 [PubMed PMID: 21521465].
85. [85] Canaud, G., Martinez, F., Noel, L.H., Mamzer, M.F., Niaudet, P., Legendre, C., Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. Transplant Rev 24 (2010), 121–128 [PubMed PMID: 20537521].
86. [86] Staeck, O., Slowinski, T., Lieker, I., et al. Recurrent primary focal segmental glomerulosclerosis managed with intensified plasma exchange and concomitant monitoring of soluble Urokinase-type plasminogen activator receptor-mediated podocyte beta3-integrin activation. Transplantation 99 (2015), 2593–2597 [PubMed PMID: 26371597].
87. [87] Barratt, J., Feehally, J., Treatment of IgA nephropathy. Kidney Int 69 (2006), 1934–1938 [PubMed PMID: 16641928].
88. [88] Lv, J., Xu, D., Perkovic, V., et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23 (2012), 1108–1116 [PubMed PMID: 22539830, Pubmed Central PMCID: 3358763].
89. [89] Fervenza, F.C., Cosio, F.G., Erickson, S.B., et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73 (2008), 117–125 [PubMed PMID: 17943078].
90. [90] Sprangers, B., Lefkowitz, G.I., Cohen, S.D., et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 5 (2010), 790–797 [PubMed PMID: 20185599, Pubmed Central PMCID: 2863969].
91. [91] Green, H., Rahamimov, R., Rozen-Zvi, B., et al. Recurrent membranoproliferative glomerulonephritis type I after kidney transplantation: a 17-year single-center experience. Transplantation 99 (2015), 1172–1177 [PubMed PMID: 25340602].
92. [92] Lien, Y.H., Scott, K., Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis 35 (2000), 539–543 PubMed PMID: 10692284.
93. [93] Farooqui, M., Alsaad, K., Aloudah, N., Alhamdan, H., Treatment-resistant recurrent membranoproliferative glomerulonephritis in renal allograft responding to rituximab: case report. Transplant Proc 47 (2015), 823–826 PubMed PMID: 25891740.
94. [94] Guiard, E., Karras, A., Plaisier, E., et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 6 (2011), 1609–1616 [PubMed PMID: 21700823].
95. [95] Lorenz, E.C., Sethi, S., Leung, N., Dispenzieri, A., Fervenza, F.C., Cosio, F.G., Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 77 (2010), 721–728 [PubMed PMID: 20130531].
96. [96] Bomback, A.S., Smith, R.J., Barile, G.R., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7 (2012), 748–756 [PubMed PMID: 22403278, Pubmed Central PMCID: 3338285].
97. [97] Gurkan, S., Fyfe, B., Weiss, L., Xiao, X., Zhang, Y., Smith, R.J., Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28 (2013), 1975–1981 [PubMed PMID: 23689905, Pubmed Central PMCID: 4428658].
98. [98] McCaughan, J.A., O'Rourke, D.M., Courtney, A.E., Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12 (2012), 1046–1051 [PubMed PMID: 22233157].
99. [99] Sanchez-Moreno, A., De la Cerda, F., Cabrera, R., et al. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 29 (2014), 2055–2059 [PubMed PMID: 24908321].
100. [100] Riella, L.V., Kidney transplant eBook. 1st ed., 2015 [274 pp., www.leoriella.com/book/; Epub May, 2015].